Purilogics

Purilogics was founded in 2013 to commercialize novel membrane chromatography technology from Clemson University, aiming to reimagine purification for faster, more efficient bioprocessing. Its key achievement was the 2022 acquisition by industrial filtration leader Donaldson Company (NYSE: DCI), which provided global scale, manufacturing muscle, and a sales network. The company's strategy is to leverage Donaldson's century of filtration expertise to expand its Purexa™ platform, targeting pain points in the rapidly growing gene therapy, cell therapy, and advanced biologics manufacturing markets.

The Purexa™ membrane chromatography platform replaces traditional resin columns with functionalized porous membranes, enabling a convection-dominated process for rapid, high-flow-rate purification of complex biologics like antibodies, viral vectors, and nucleic acids.

Purilogics competes with traditional resin giants (Cytiva, Merck) and established membrane chromatography providers (Sartorius). Its key advantages are superior binding capacity at high flow rates for large molecules, linear scalability from R&D to GMP, and the manufacturing and commercial backing of its parent company, Donaldson.